GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
E

Edding Genor Group Holdings 6998.HK · HKD

Health Care · HKEX · 🇭🇰 Hong Kong

Compare

1.59

0.00%

Close of 9 Nov 2026, in HKD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Edding Genor Group Holdings

Its shares trade on HKEX under the ticker 6998.HK. It has been listed since 7 October 2020. In the fiscal year to 31 December 2025, it reported revenue of CN¥2.70bn and net income of CN¥433.0m. At that date it held total assets of CN¥6.61bn and shareholders' equity of CN¥3.86bn.

Genor Biopharma Holdings Ltd. engages in the development and commercialization of oncology and autoimmune drugs. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2020-10-07. The firm focuses on the development and commercialization of oncology and autoimmune drugs. The firm's main drugs include lerociclib (GB491), coprelotamab (GB221), geptanolimab (GB226), GB492, GB242 and GB223. The firm mainly conducts its businesses in the China market.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
7 Oct 2020
Employees
222

Leadership

Pay as last reported

  • Dr. Feng GuoChief Executive Officer, since 2020CN¥41.2m
  • Mr. Chengyi WengChief Financial Officer, Executive Director, since 2024
  • Mr. Wende ChenChief Operation Officer
  • Mr. Qibin LiangChief Technology Officer
  • Dr. Shuhua HanChief Scientific Officer
  • Ms. Yao ChenVice President - Regulatory Affairs
  • Mr. Jun LinVice President - Quality Analysis
  • Mr. Qingtang DuanGeneral Manager - Yuxi Genor
  • Mr. Mark KubikChief Business Officer
  • Ms. Tong LiChief Medical Officer
  • Mr. Tak Wai IpCompany Secretary
  • Mr. Yi LiuNon-Executive Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Company is focused on oncology and autoimmune drug development and commercialization.
  • Headquartered in Shanghai with 222 employees.
  • IPO took place in 2020-10-07.

Weaknesses

  • Company's main drugs are not specified as approved or in clinical trials.
  • Business is primarily limited to the China market.
  • No information provided on drug approval status or commercial success.

Opportunities

  • Potential for expansion into international markets beyond China.
  • Growth in biotechnology sector could benefit the company.
  • Development of new drugs like lerociclib and coprelotamab may lead to market opportunities.

Threats

  • Dependence on the China market may pose risks from regulatory changes.
  • Lack of information on drug approval status could hinder market entry.
  • Competition in the biotechnology sector may impact the company's position.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.